Literature DB >> 29502112

Hyperhidrosis - Sweating Sites Matter: Quality of Life in Primary Hyperhidrosis according to the Sweating Sites Measured by SF-36.

Alexander Shayesteh1, Urban Janlert2, Elisabet Nylander1.   

Abstract

BACKGROUND: Primary hyperhidrosis has negative impacts on quality of life. The aim of this study was to investigate whether the impacts of primary hyperhidrosis on quality of life are different depending on the localisation of the sweating.
METHOD: We compiled background data, Hyperhidrosis Disease Severity Scale (HDSS), and Short-Form Health Survey (SF-36) post hoc results from 2 previous studies. Cases who described only 1 site as their most problematic area of sweating were included (n = 160/188) while individuals with multifocal primary sites of hyperhidrosis were excluded (n = 28/188).
RESULTS: Individuals included were 11-62 years old with a mean age of 30.2 ± 10.4 years, and axillary hyperhidrosis (65.6%) was the most common type of hyperhidrosis. Comorbidities were more common when hyperhidrosis was reported in other than the axillary, palmar, and plantar regions. Excluding comorbidities showed the lowest SF-36 mental component summary scores for axillary (41.6 ± 11.6), palmar (40.0 ± 9.4), and plantar hyperhidrosis (41.1 ± 13.7). The HDSS showed the highest proportion of severe cases in axillary (60.6%) and palmar (51.5%) hyperhidrosis (p < 0.01) while mild cases were more often observed in plantar (60%), facial (83.3%), and other sites (85.7%) in primary hyperhidrosis (p < 0.01).
CONCLUSION: Our results indicate that impairments in quality of life can be different depending on the manifestation of primary hyperhidrosis on the body. This can have an influence on how patients with hyperhidrosis could be prioritised in health care. Subgroup samples affected by facial hyperhidrosis and other sites of primary hyperhidrosis were however small, and more research is required to verify our findings.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Hyperhidrosis; Quality of life; Survey

Mesh:

Year:  2018        PMID: 29502112     DOI: 10.1159/000486713

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

1.  The health-related quality of life in hyperhidrosis and co-morbidities.

Authors:  Ole B Pedersen; Gregor B E Jemec; Mattias A S Henning; Kristina S Ibler; Isabella Loft; Sisse R Ostrowski; Christian Erikstrup; Kaspar R Nielsen; Mie T Bruun; Henrik Ullum; Maria Didriksen; Khoa M Dinh
Journal:  Qual Life Res       Date:  2022-02-22       Impact factor: 4.147

Review 2.  Treatment of Hyperhidrosis: An Update.

Authors:  Mattias A S Henning; Dorra Bouazzi; Gregor B E Jemec
Journal:  Am J Clin Dermatol       Date:  2022-07-01       Impact factor: 6.233

3.  The Impact of COVID-19 on Hyperhidrosis Patients in the Mental Health and Quality of Life: A Web-Based Surveillance Study.

Authors:  Wongi Woo; Jooyoung Oh; Bong Jun Kim; Jongeun Won; Duk Hwan Moon; Sungsoo Lee
Journal:  J Clin Med       Date:  2022-06-21       Impact factor: 4.964

4.  Two-week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis.

Authors:  Tomoko Fujimoto; Hiromichi Okatsu; Hiroshi Miyama
Journal:  J Dermatol       Date:  2022-04-08       Impact factor: 3.468

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.